OBJECTIVE: To assess the epidemiology and outcome of patients with cirrhosis following critical care unit admission. DESIGN: Retrospective cohort study. SETTING: Critical care units in England, Wales, and Northern Ireland participating in the U.K. Intensive Care National Audit and Research Centre Case Mix Programme. PATIENTS: Thirty-one thousand three hundred sixty-three patients with cirrhosis identified of 1,168,650 total critical care unit admissions (2.7%) admitted to U.K. critical care units between 1998 and 2012. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Ten thousand nine hundred thirty-six patients had alcohol-related liver disease (35%). In total, 1.6% of critical care unit admissions in 1998 had cirrhosis rising to 3.1% in 2012. The crude critical care unit mortality of patients with cirrhosis was 41% in 1998 falling to 31% in 2012 (p < 0.001). Crude hospital mortality fell from 58% to 46% over the study period (p < 0.001). Mean(SD) Acute Physiology and Chronic Health Evaluation II score in 1998 was 20.3 (8.5) and 19.5 (7.1) in 2012. Mean Acute Physiology and Chronic Health Evaluation II score for patients with alcohol-related liver disease in 2012 was 20.6 (7.0) and 19.0 (7.2) for non-alcohol-related liver disease (p < 0.001). In adjusted analysis, alcohol-related liver disease was associated with increased risk of death (odds ratio, 1.51 [95% CI, 1.42-1.62; p < 0.001]) with a year-on-year reduction in hospital mortality (adjusted odds ratio, 0.95/yr, [0.94-0.96, p < 0.001]). CONCLUSIONS: More patients with cirrhosis are being admitted to critical care units but with increasing survival rates. Patients with alcohol-related liver disease have reduced survival rates partly explained by higher levels of organ failure at admission. Patients with cirrhosis and organ failure warrant a trial of organ support and universal prognostic pessimism is not justified.
OBJECTIVE: To assess the epidemiology and outcome of patients with cirrhosis following critical care unit admission. DESIGN: Retrospective cohort study. SETTING: Critical care units in England, Wales, and Northern Ireland participating in the U.K. Intensive Care National Audit and Research Centre Case Mix Programme. PATIENTS: Thirty-one thousand three hundred sixty-three patients with cirrhosis identified of 1,168,650 total critical care unit admissions (2.7%) admitted to U.K. critical care units between 1998 and 2012. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Ten thousand nine hundred thirty-six patients had alcohol-related liver disease (35%). In total, 1.6% of critical care unit admissions in 1998 had cirrhosis rising to 3.1% in 2012. The crude critical care unit mortality of patients with cirrhosis was 41% in 1998 falling to 31% in 2012 (p < 0.001). Crude hospital mortality fell from 58% to 46% over the study period (p < 0.001). Mean(SD) Acute Physiology and Chronic Health Evaluation II score in 1998 was 20.3 (8.5) and 19.5 (7.1) in 2012. Mean Acute Physiology and Chronic Health Evaluation II score for patients with alcohol-related liver disease in 2012 was 20.6 (7.0) and 19.0 (7.2) for non-alcohol-related liver disease (p < 0.001). In adjusted analysis, alcohol-related liver disease was associated with increased risk of death (odds ratio, 1.51 [95% CI, 1.42-1.62; p < 0.001]) with a year-on-year reduction in hospital mortality (adjusted odds ratio, 0.95/yr, [0.94-0.96, p < 0.001]). CONCLUSIONS: More patients with cirrhosis are being admitted to critical care units but with increasing survival rates. Patients with alcohol-related liver disease have reduced survival rates partly explained by higher levels of organ failure at admission. Patients with cirrhosis and organ failure warrant a trial of organ support and universal prognostic pessimism is not justified.
Authors: Thierry Gustot; Javier Fernandez; Elisabet Garcia; Filippo Morando; Paolo Caraceni; Carlo Alessandria; Wim Laleman; Jonel Trebicka; Laure Elkrief; Corinna Hopf; Pablo Solís-Munoz; Faouzi Saliba; Stefan Zeuzem; Augustin Albillos; Daniel Benten; José Luis Montero-Alvarez; Maria Teresa Chivas; Mar Concepción; Juan Córdoba; Aiden McCormick; Rudolf Stauber; Wolfgang Vogel; Andrea de Gottardi; Tania M Welzel; Marco Domenicali; Alessandro Risso; Julia Wendon; Carme Deulofeu; Paolo Angeli; François Durand; Marco Pavesi; Alexander Gerbes; Rajiv Jalan; Richard Moreau; Pere Ginés; Mauro Bernardi; Vicente Arroyo Journal: Hepatology Date: 2015-05-29 Impact factor: 17.425
Authors: Rafael Bañares; Frederik Nevens; Fin Stolze Larsen; Rajiv Jalan; Agustín Albillos; Matthias Dollinger; Faouzi Saliba; Tilman Sauerbruch; Sebastian Klammt; Johann Ockenga; Albert Pares; Julia Wendon; Tanja Brünnler; Ludwig Kramer; Philippe Mathurin; Manuel de la Mata; Antonio Gasbarrini; Beat Müllhaupt; Alexander Wilmer; Wim Laleman; Martin Eefsen; Sambit Sen; Alexander Zipprich; Teresa Tenorio; Marco Pavesi; Hartmut H-J Schmidt; Steffen Mitzner; Roger Williams; Vicente Arroyo Journal: Hepatology Date: 2013-02-15 Impact factor: 17.425
Authors: E Cholongitas; M Senzolo; D Patch; K Kwong; V Nikolopoulou; G Leandro; S Shaw; A K Burroughs Journal: Aliment Pharmacol Ther Date: 2006-04-01 Impact factor: 8.171
Authors: Vincent Das; Pierre-Yves Boelle; Arnaud Galbois; Bertrand Guidet; Eric Maury; Nicolas Carbonell; Richard Moreau; Georges Offenstadt Journal: Crit Care Med Date: 2010-11 Impact factor: 7.598
Authors: Richard Moreau; Rajiv Jalan; Pere Gines; Marco Pavesi; Paolo Angeli; Juan Cordoba; Francois Durand; Thierry Gustot; Faouzi Saliba; Marco Domenicali; Alexander Gerbes; Julia Wendon; Carlo Alessandria; Wim Laleman; Stefan Zeuzem; Jonel Trebicka; Mauro Bernardi; Vicente Arroyo Journal: Gastroenterology Date: 2013-03-06 Impact factor: 22.682
Authors: Manil D Chouhan; Stuart Andrew Taylor; Anisha Bhagwanani; Charlotte Munday; Mark A Pinnock; Tom Parry; Yipeng Hu; Dean Barratt; Dominic Yu; Rajeshwar P Mookerjee; Steve Halligan; Sue Mallett Journal: BMJ Open Date: 2022-05-02 Impact factor: 2.692
Authors: Moayed N Alkhlewi; Hasan M Al-Dorzi; Farhan Z Alenezi; Abdulrahman M Farhat; Hani Tamim; Musharaf Sadat; Felwa Bin Humaid; Yaseen M Arabi Journal: Saudi Med J Date: 2021-12 Impact factor: 1.422